Latest News

A selection of recent news and views from Catapult Ventures follows...

The AMR Centre signs agreement with Microbiotix to co-develop treatment for gonorrhoea

The AMR Centre (AMRC) has today announced a multi-year co-development agreement with Massachusetts-based clinical stage biopharmaceutical company Microbiotix, Inc. to progress a novel treatment to tackle the bacterium that is responsible for gonor...

Blueberry Therapeutics announces new Clinical Science Lead

Blueberry Therapeutics are delighted to welcome Kerry Nield as Clinical Science Lead, with responsibility for clinical trial design and pipeline implementation including clinical scientific expertise, clinical strategy and product development plan...

Cytox MedNous coverage: Genetic risk assessment in Alzheimer's disease

Dr Alex Gibson, Business Development Officer at Cytox discusses in MedNous how to predict a person’s genetic risk of developing Alzheimer's using Polygenic Risk Scores. First application is identifying patients most suitable to enter clinica...

Rinicare receives funding support from Innovate UK

Rinicare and The University Hospitals of Morecambe Bay NHS Trust are delighted to announce that they have received funding support from Innovate UK to proceed with a joint research project that will collect real-life evidence of the benefits of Ri...

Catapult invests in Biohabit through the GM&C Life Sciences Fund

Catapult has completed a seed investment into Alderley Park based Biohabit through the Greater Manchester and Cheshire Life Sciences Fund. Biohabit are developing a salivary test for diagnosis of heart failure, that hopes to replace the need for...

From our portfolio

Blueberry Therapeutics

Biotechnology

Blueberry Therapeutics is a biotechnology company developing a range of anti-microbial products u...

viewview our portfolio

Our Team

Rob Carroll

view complete team

Contact us

Binder House
7 Narborough Wood Park
Desford Road
Enderby
Leicester
LE19 4XT

Tel: 0116 238 8200

email